Muhammad Parvaz, PhD
Muhammad Adeel Parvaz (Preferred Name)
- ASSISTANT PROFESSOR | Psychiatry
- ASSISTANT PROFESSOR | Neuroscience
Research Topics:
Addiction, Biomedical Sciences, Cognitive Neuroscience, MRI, Neurobiology, Neuromodulation, Neurophysiology, Neuroscience, Prefrontal Cortex, Psychiatry, Schizophrenia, Systems NeuroscienceDr. Parvaz's primary research interest includes studying cognitive-affective interactions underlying deficits in motivation, reinforcement learning and inhibitory control in mental health disorders, specifically in substance use disorders, using behavioral, computational and neuroimaging techniques. As a cognitive neuroscientist with a background in biomedical engineering, he places special emphasis on understanding disease mechanisms with an eye towards developing clinically useful biomarkers to accelerate bench-to-bedside translation of lab-based assessments. His research involves tracking neurobehavioral plasticity during the onset of as well as remission from substance use disorders. At the clinical translation side of this work, he is developing and testing interventions for craving reduction during behavioral and neuromodulation techniques. In parallel, he is also interested in studying the onset and development of aberrant cognitive-affective interaction in adolescents as well as risk factors that render some youth vulnerable to develop psychopathological phenotypes (e.g., substance use disorder, eating disorders and psychosis). For these studies, his group uses a comprehensive multimodal approach with multiscale modeling of environmental (socio-economic factors), clinical (rating scales), behavioral (cognitive tasks), molecular (MR spectroscopy and blood based inflammatory markers), physiological (EEG) and circuit-level (fMRI) biomarkers to more precisely define the phenotype of interest and to track or predict individualized outcomes (e.g., development of substance use disorders in adolescents and relapse in treatment seeking addicted individuals).
Multi-Disciplinary Training Areas
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Development Regeneration and Stem Cells [DRS], Neuroscience [NEU]Education
PhD, Stony Brook University
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Parvaz did not report having any of the following types of financial relationships with industry during 2021 and/or 2022: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.